Greenland Mines (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508, covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems.
The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (ALS) and other neuromuscular disorders. ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to muscle weakness and eventual paralysis. The Klotho protein has been studied for its potential anti-aging and neuroprotective effects, making it a promising target for treating such conditions.
Greenland Mines is a Nasdaq-listed company with two operating divisions: Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and Biotech, including Klotho’s KLTO-202 primary indication for ALS. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
This patent grant represents a significant milestone for Greenland Mines’ biotech division, as it provides robust intellectual property protection in Australia, a key market for pharmaceutical development. The exclusive license for the Klotho gene therapy technology positions the company to advance its pipeline for neuromuscular diseases, potentially offering new treatment options for patients with ALS. The KLTO-202 program aims to leverage the neuroprotective properties of the Klotho protein to slow or halt disease progression.
The broader implications of this patent extend to the field of gene therapy, where intellectual property is critical for attracting investment and partnerships. Greenland Mines’ ability to secure patent protection in Australia may facilitate clinical development and commercialization efforts in the region. The company’s focus on rare earth mining and biotech highlights a diversified approach to creating value across different sectors.
For more details, the full press release is available at https://nnw.fm/PVbbH. The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These include factors beyond management's control, as detailed in the company's filings with the SEC.
